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Background. Hormone replacement therapy (HRT) is recommended to post-menopausal women to control menopausal
symptoms and prevent osteoporosis. The management of women with peripheral arterial disease (PAD) and who are taking
HRT is controversial.
Aim. To summarise what is known about HRT and its effect on the natural progression of PAD and its subsequent
treatment.
Methods. A MEDLINE (1966e2004) and Cochrane library search for articles relating to HRTand PAD was undertaken.
Results. The potential benefits of unopposed estrogen therapy on atherosclerotic progression and limb microcirculation are
outweighed by the increased risk of endometrial dysplasia and thrombotic complications. Only one major study (Rotter-
dam) specifically assessed the impact of HRT on the clinical course of PAD. The findings suggested a decreased risk of
PAD among healthy post-menopausal women taking HRT which contrasts with the sub-group analyses of other major
studies (HERS/HERS II). HRT appears to reduce the primary success rates of both endovascular and open surgical revas-
cularisation in patients with PAD.
Conclusions. Further studies are required to investigate the effects of HRTon the progression of PAD and its management.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The effect of hormone replacement therapy (HRT) on
the prevention and outcome of cardiovascular disease
has been the subject of a number of clinical trials. Very
few studies, however, have directly addressed the ef-
fect of HRT on peripheral arterial disease (PAD).1
Three important clinical dilemmas exist when manag-
ing PAD in postmenopausal women:
1. Should patients with PAD be advised to start, con-
tinue or discontinue taking HRT and how does this
advice impact upon disease progression?
2. Does HRT impact on the benefits of best medical
therapy (BMT) in patients with PAD?
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Department of Vascular and Endovascular Surgery, Netherwood
House, Solihull Hospital, Birmingham B91 2JL, UK.
E-mail address: donald.adam@heartofengland.nhs.uk8–5884/000569+ 07 $32.00/0  2007 European Society for Vascu3. Does HRT influence the short and long-term out-
comes of vascular and endovascular intervention
for the treatment of PAD?
Methods
We performed a MEDLINE (1966e2004) and Co-
chrane library search looking for articles relating to
HRT, its effect on arterial physiology and the influence
this has on the management of PAD. The terms hor-
mone therapy, HRT, menopause, estrogens and pro-
gestogens were included amongst others. These
were linked with terms such as cardiovascular dis-
ease, peripheral vascular disease and peripheral arte-
rial disease. Further articles were identified by
following MEDLINE links, by cross-referencing from
the reference lists of major articles and by following
citations for these studies. The studies were then
graded and prioritised according to the level of the
evidence presented.lar Surgery. Published by Elsevier Ltd. All rights reserved.
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Studies examining the effect of HRTon cardiovascular
disease progression and outcomes are summarised in
Table 1.
The effect of HRT on the arterial wall
and atherosclerosis
Several studies2e5 have examined the effects of HRT
in relation to coronary events, but few have examined
its impact on the progression of atherosclerosis in the
peripheral arterial system. Change in carotid intima-
media thickness correlates well with the sub-clinical
progression of generalized atherosclerosis.6 Various
studies, including one large randomised, double-
blind, placebo-controlled trial (the Estrogen in the
Prevention of Atherosclerosis (EPAT) study)7 mea-
sured carotid intima-media thickness and demon-
strated that unopposed estrogen therapy slows or
halts the progression of atherosclerosis.8 By contrast,
other studies such as the Atherosclerosis Risk in Com-
munities (ARIC) study,9 and the more recent Healthy
Women’s Study10 reported no beneficial effect of HRT
on carotid intimal thickening. The different findings
of these studies may be due to the different types of
estrogen used (17beta-estradiol vs conjugated equine
estrogen) and the fact that by studying different age
groups, different stages of disease were targeted.
This is particularly relevant since patients seen by
vascular specialists are more likely to be older with
more advanced atherosclerosis and may not enjoy
the full benefits seen in healthy postmenopausal
women without pre-existing cardiovascular disease.7
The differences in the effect that estrogen has
on different stages of atherosclerosis may be
secondary to its effects on the endothelium which
becomes dysfunctional early in the development of
atherosclerosis;11 this said there is evidence that
estrogen promotes endothelial function and augments
endothelium-dependent vasodilatation at the micro-
and macrovascular levels. Conjugated equine estro-
gen has been shown to reduce the accumulation of
collagen and attenuate the fall of elastin content in
monkey aortas.12 In this way, HRT may also have
a beneficial effect on arterial wall stiffness.
HRT and the coagulation cascade
Clinical trials2 and experimental evidence indicates
that the overall effect of HRT is to stimulate coagula-
tion, inhibit anticoagulation and stimulate fibrinoly-
sis.13e15 This effect is by no means certain, however,Eur J Vasc Endovasc Surg Vol 34, November 2007as both the Postmenopausal Estrogen/Progestin Inter-
ventions (PEPI) trial15 and other experimental studies
have demonstrated a reduction in plasma fibrinogen
levels in those on combined HRT (cHRT). It is, as
yet, unclear to what extent the addition of progester-
one attenuates the oestrogenic prothrombotic ten-
dency.16 Subgroup analysis of data from the Heart
and Estrogen/Progestin Replacement (HERS) study2
demonstrated that estrogen increases the risk of early
acute cardiovascular events in those women geneti-
cally predisposed to arterial thrombosis.17,18 In this
study, an early increased risk of venous thromboem-
bolism (VTE) was also identified and this has been
reinforced by findings in other prospective and
case-control studies.14 HRT is now contraindicated
in patients with a history of myocardial infarction
or VTE.19 The prothrombotic properties of HRT may
account for the increased risk of thrombotic cardio-
vascular events in the first year after starting cHRT,
as demonstrated in the HERS and Rotterdam studies,
and this risk may be attenuated beyond the first year
by the beneficial effect on lipid profile. Patients with
PAD starting HRT may be at increased immediate
risk of thromboembolic events that extends for weeks
following cessation of drug administration. While oral
HRT at least doubles the risk of VTE,2,20 the Estrogen
and Thromboembolism Risk Study Group (ESTHER)21
found transdermal HRT does not appear to have the
same effect. It would not be unreasonable to stop
oral HRT 4e6 weeks prior to endovascular or surgical
revascularisation particularly in those patients with
PAD who have additional risk factors for VTE.
The impact of different types of HRT on arterial
structure and physiology
The dose and types of estrogen and progesterone used
inmajor studies of post-menopausal HRTare shown in
Table 2. In the UK, there are a range of combined treat-
ments available but the most widely used contain
1e2 mg of estradiol (Climesse, Climagest, Elleste-
Duet, Femoston, Nuvelle etc.) or 0.625 mg
conjugated equine estrogen (Prempak C). The type
and dose of progestin is more variable but most treat-
ments in common use include a dose of 1 mg norethis-
terone acetate for 10e14 days (Climesse, Climagest,
Elleste-Duet, Evorell) or 75 mg of levonorgestrel
(Prempak C, Nuvelle).14 The significance, if any,
of these variations is unclear. Acute administration
of oestrogen is known to improve endothelium-
dependent flow in the microcirculation in healthy
postmenopausal women,22 and many studies in both
animals and human subjects have suggested a
Summary RR (95%CI)
Route
oral no overall reduction in CHD
events in women with
established coronary disease.
Higher risk of CHD in first
year
0.99 (0.8e1.22)
oral Hormone therapy did not
reduce risk of cardiovascular
events in women with CHD
1.0 (0.77e1.29)
oral no benefit fot primary CHD
prevention
1.29 (1.02e1.63)
oral No alteration in progression of
coronary atherosclerosis in
women with established
disease
N/A
oral N/A
oral In PNP women with recent
CVA HRT did not reduce risk
of any cardiac event
1.2 (0.5e2.5)
oral Average rate of progression of
subclinical atherosclerosis
was slower in healthy PMP
women taking Oestradiol
N/A
oral estrogen alone or in
combination with
progesterone improves
lioproteins and lowers
fibrinogen levels in PMP
women
N/A
oral N/A
iv/oral acute hormaone therapy did
not reduce ischaemia in PMP
women with unstable angina
N/A
iv/oral N/A
oral May not be CVS beneficial in
PMP women
N/A
oral Cardiovascular protective 0.69 (0.54e0.86)
oral No Cardiovascular protection 0.9 (0.74e1.08)
oral Cardiovascular protective 0.53 (0.3e0.87)
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2007Table 1. Studies examining the effect of HRT on cardiovascular disease progression and outcome
Trial Author Type Patient no. Mean follow-up HRT
Type
HERS Hulley et al.2 RCT 2763 4.1 years (conjugated equine)
Oestrogenþ Progestin
HERS II Grady et al.3 RCT 2763 6.8 years (conjugated equine)
Oestrogenþ Progestin
WHI Writing group5 RCT 16608 5.2 years Oestrogenþ Progestin
ERA Herrington et al.4 RCT 309 3.2 years (conjugated equine)
Oestrogen
(conjugated equine)
Oestrogenþ Progestin
WEST Viscoli et al.57 RCT 664 2.8 years Oestrogen
EPAT Hodis et al.7 RCT 222 2 years Oestradiol
PEPI Writing group15 RCT 875 3 years conjugated equine oestrogen
conjugated equine
oestrogenþ Progesterone
Schulman et al.58 RCT 293 6 months iv oestrgen/ oral oestrogen
iv oestrgen/ oral
oestrogenþ progestin
Teede et al.27 RCT 59 2 years OestradiolþNorethisterone
Falkeborn et al.59 Prospective
cohort study
23174 5.8 years Conjugated Oestrogen/
oestradiol
Other oestrogen
Oestradiolþ Lenonogesterola
572 R. S. M. Davies et al.Table 2. The dose and types of oestrogen and progesterone used in major studies of post-menopausal HRT
Trial Route Oestrogen Progesterone
Type Dose Type Dose
HERS2 oral conjugate equine 0.625 mg medroxyprogesterone acetate 2.5 mg
HERS II3 oral conjugate equine 0.625 mg medroxyprogesterone acetate 2.5 mg
WHI5 oral conjugate equine 0.625 mg medroxyprogesterone acetate 2.5 mg
ERA4 oral conjugate equine 0.625 mg medroxyprogesterone acetate 2.5 mg
WEST57 oral 17b-estradiol 1 mg NA NA
EPAT7 oral miconized 17b-estradiol 1 mg NA NA
PEPI15 oral conjugate equine 0.625 mg cyclical medroxyprogesterone acetate 10 mg/2.5 mg
cyclic micronized progesterone 200 mgrelationship between estrogen and increased produc-
tion of nitric oxide (NO), a potent vasodilator. One
study showed that administration of estrogen in-
creased levels of cGMP and presumably therefore
NO in postmenopausal women.23 This effect did not
occur when progesterone was also administered and
interestingly the effect was only seen in smokers. In-
deed, when vascular bed reactivity and the levels of
NO in the circulation were examined in patients on
oestrogen therapy compared with subjects on cHRT,
the beneficial effects of long-term estrogen therapy
appeared to be abolished by the addition of a Pro-
gestin.24,25 One study demonstrated improved skin
vasodilatation in response to vasodilators in postmen-
opausal women taking estrogen replacement
therapy.11 Progestins, possibly by increasing plasma
renin activity, have a potential pressor effect which
may antagonise the effect of estrogen on vascular
tone.26 Animal studies have also shown that medroxy-
progesterone acetate may inhibit the beneficial effect
estrogen has on connective tissue metabolism.12 These
findings may explain why continuous cHRT has been
shown to have no effect on systemic arterial compli-
ance, pulse wave velocity and endothelial function in
healthy postmenopausal women.27
The impact of HRT on the clinical course of PAD
TheRotterdamstudy,1 a population-basedprospective,
longitudinal, observational study of 2196 women aged
55 to 80 years, suggested that HRT given for a year or
more was associated with a decreased risk of PAD
among postmenopausal women. However an impor-
tant study limitationwas the fact that 91% of the partic-
ipants were taking unopposed estrogen. The findings
of this study, however, appear to contradict several con-
trolled trials2e5 examining the effects ofHRTon the cor-
onary and cerebral vasculature. Analysis of data from
a group of patients with known coronary heart disease
(CHD) in theHERS study2,3,28 showed thatHRTdidnot
significantly lower the number of peripheral arterial
events in this group of patients.Eur J Vasc Endovasc Surg Vol 34, November 2007HRT and cardiovascular risk factor management
The recent Womens Health Initiative (WHI)5 and
the HERS II trials3 have shown no cardioprotective
properties associated with HRT in postmenopausal
women and this has also been demonstrated in
a meta-analysis.29,30 Women with pre-existing cardio-
vascular disease were found to be at increased risk of
cardiovascular events in the first year after commenc-
ing HRT2 while longer term use may actually protect
against development of PAD.1
The HERS and HERS II trials did not demonstrate
any significant difference in coronary events between
women taking HRT and aspirin, and women taking
HRT without aspirin (RR: 0.96(95%CI, 0.7e1.31)
HRTþAspirin vs. 1.01(95%CI, 0.83e1.22) HRT
alone).2,3
Estrogen therapy has consistently been shown to
reduce levels of circulating low density lipoproteins
(LDL) and increase levels of high density lipoproteins
(HDL),2,15,31,32 and this may prevent progression of
atherosclerosis.33e35 This does not, however, mean
that the routine use of cHRT results in direct clinical
benefit via this mechanism. Indeed, one of the most
important randomised controlled trials (HERS) failed
to show an overall cardiovascular benefit despite sig-
nificant changes in lipid profiles.4 During the HERS
trial, a 14% decrease in LDL cholesterol occurred by
the end of the first year of treatment compared with
3% in the placebo group. Despite this there appeared
to be an increase in primary CHD events during this
year (but a decrease in subsequent years). This may
be related to the use of progesterone. It was shown
in the PEPI trial that progesterone lessens the effect
of estrogen on HDL cholesterol, and it is thought
that progesterone attenuates the beneficial effect of
oestrogen.15,36,37 However, two other trials using com-
bined hormones have shown conflicting results.20,38,39
Statins (HMG-CoA reductase inhibitors) have
been shown to reduce mortality in patients with cor-
onary artery disease and elevated low-density lipo-
protein (LDL) levels.40,41 However, the absence of
reductions in mortality by any other lipid lowering
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suggests that non-lipid effects may be important
in mediating these benefits.42 Statins inhibit GTPase
activation and preserve vascular function indepen-
dently of their lipid lowering properties. Specifically,
statins increase the bioavailability of endothelium-
derived nitric oxide (NO) -a potent vasodilator-
through the up regulation of endothelial nitric
oxide synthetase (eNOS).43 Both human and animal
models indicate that estrogen also has potent
stimulatory effects on eNOS expression and activity.44
The clinical beneficial of this effect is doubtful,
however, in light of the lack of mortality benefits re-
ported by the HERS trial. An alternative hypothesis
is that estrogen is associated with an early prothrom-
botic effect which acts in conflict with a more grad-
ual beneficial effect on prevention of progression of
atherosclerosis.13 Further comparison of the actions
of statins and estrogen would appear to offer some
support to this hypothesis: statins also appear to
have an anticoagulation effect and this may account
for some of their short term mortality benefits.
Although simvastatin is better at lowering LDL
cholesterol than oestrogen, one study did show that
oestrogen replacement therapy was better at raising
HDL cholesterol. It concluded that there was a modest
additional benefit of adding oestrogen to a statin in re-
lation to lipid profile outcome49 Statins may also pro-
tect against some of the apparent negative effects of
HRT seen in the immediate treatment period. An anal-
ysis of the HERS trial found that the increased cardio-
vascular mortality risk found for HRTusers in the first
year was attenuated by statins.45 A further beneficial
effect of unopposed estrogen was shown in the
Asymptomatic Carotid Artery Progression Study
where changes in carotid intima-media thickness
were reduced in women taking unopposed estrogen
and no additional effect was identified in women re-
ceiving lovastatin.46 In addition to the beneficial ef-
fects on lipid profiles and vascular beds, unopposed
estrogen therapy seems to have a favourable effect
on glucose metabolism in patients with diabetes
mellitus.47
There is a lack of consensus about the effects of
HRT on blood pressure (BP). Cross-sectional studies
have generally reported HRT as having no effect on
BP.37,48,49 The PEPI trial15 did not show HRT (estrogen
or combination estrogen and progesterone) as having
any effect on BP in 875 patients followed up for
3 years. This may be related to the counter balance
vasopressor effects of progestin to the vasodilator
effects of oestrogen. In contrast, Scuteri et al. reported
post-menopausal women taking both oestrogen and
progestin to have a smaller increase in systolic BPcompared to those not taking HRTover a mean follow
up period of 5.7 years.50 These contradictory data sug-
gest that national hypertension guidelines should be
adhered to irrespective of the individuals HRT status.
HRT and the medical management of
intermittent claudication
Although no study has examined the effect of HRT
on claudication distance in patients with PAD, estro-
gen therapy has been shown to improve exercise
capacity in postmenopausal women with CHD
possibly as a result of short term improvements in
endothelial-dependent and non-endothelial-dependent
vasodilation.51
HRT and peripheral revascularisation
HRT has been shown to increase circulating levels
of coagulation activation markers and it is well-
recognised that patients with PAD have a pro-
thrombotic haemostatic derangement.52 Only one
study has examined the influence of HRT on the
outcome of peripheral angioplasty/stenting. A longi-
tudinal observational study of 126 iliac angioplasties
and 144 stents over a 5 year period found HRT
significantly reduced primary patency rates (HRT
users: 49% vs. non-HRT users: 74% 5-year primary
patency rate).53 In another study examining the
outcome of femoro-popliteal bypass grafting in
women, HRT emerged as the only predictor of dimin-
ished primary graft patency54 with the risk of graft
failure increasing with use of prosthetic material.
The same findings applied irrespective of whether
the subjects were on estrogen alone or cHRT.
Discussion
In summary, unopposed oestrogen has an overall
beneficial effect in preventing progression of athero-
sclerosis. There is an initial prothrombotic effect of
treatment, which may lead to an increase in both arte-
rial and venous thrombotic effects within the first
year, with subsequent improvement in the rate of
these events occurring possibly as a consequence of
improved lipid profile. The addition of progesterone
therapy (cHRT) appears to attenuate any beneficial ef-
fects from estrogen. In view of the high risk of endo-
metrial dysplasia from unopposed estrogen15 it is
inadvisable to prescribe unopposed estrogen to post-
menopausal women who have not had an hysterec-
tomy. Those who have undergone hysterectomy may
derive some benefit from unopposed estrogen;
574 R. S. M. Davies et al.however, this group of patients has been excluded
from most studies. Alternatives to ‘standard’ HRT,
such as selective estrogen receptor modulators (e.g.
raloxifene), appear to have beneficial effects on lipids
without the deleterious effects on coagulation13 but
there are no data assessing their effect on PAD.
To address the important clinical dilemmas for the
vascular specialist, we recommend to our patients
with PAD that they should continue their HRT as
there appears to be no significant effect on the preven-
tion or progression of PAD (other than perhaps im-
proving ability to increase exercise capacity in those
with concomitant CHD).51 However, unless strong
clinical indications exist, we advise patients with
PAD against starting on HRT in view of the initial in-
crease in thrombotic cardiovascular events up to one
year. This may also apply to patients with PAD who
are admitted for any type of surgery.
There is currently no clear evidence supporting the
routine discontinuation of HRT prior to surgery. The
Royal College of Obstetricians and Gynaecologists
currently advise that HRT should be viewed as
a risk factor for VTE and recommend the addition of
appropriate thromboembolic prophylaxis, but not
the routine cessation of HRT, prior to surgery.55 In
contrast, the current advice in the British national For-
mulary (BNF) is to stop treatment 4e6 weeks prior to
surgery.14 It is well established that PAD is associated
with a resting prothrombotic state which correlates
with disease severity and that patients undergoing
lower limb revascularisation procedures are at a high
risk of peri-operative cardiac thrombotic events.52,56
Furthermore, HRT may have a deleterious effect on
the success of both endovascular and open surgical
revascularisation.53,54 In view of these factors we
currently advise our patients to stop HRT 6 weeks
prior to surgical or endovascular intervention.
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